Table 2.

Hazard ratios of methods with sufficient power (>80%) for bevacizumab-treated patients only at first and second follow-up (FU1 and FU2)

Method	HR (95% CI) FU1	P-value	HR (95% CI) FU2	P-value
1. 2D RANO	5.53 (3.12–9.80)	<.001	2.44 (1.46–4.08)	.001
2. Contrast-enhancing volume	7.21 (3.20–16.22)	<.001
4. Contrast-enhancing + FLAIR volume	5.94 (3.06–11.53)	<.001	2.35 (1.32–4.19)	.004
5. Subtraction + FLAIR volume	5.63 (2.66–11.93)	<.001